Synergy Asset Management LLC Has $3.37 Million Holdings in Medtronic PLC $MDT

Key Points

• Synergy Asset Management LLC decreased its stake in Medtronic by 86.4% in Q4, selling 222,726 shares and ending the period with 35,072 shares valued at $3.37 million.
• Medtronic beat the quarter with $1.36 EPS versus a $1.34 estimate and $9.02 billion in revenue (+5.8% YoY), and set FY2026 guidance of 5.62–5.66 EPS versus a consensus near 5.46.
• The company declared a $0.71 quarterly dividend (annualized $2.84, ~3.2% yield), while an EVP sold 52,524 shares for roughly $5.13 million, reducing insider ownership to about 0.26%.

Synergy Asset Management LLC decreased its stake in Medtronic PLC (NYSE:MDT - Free Report) by 86.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,072 shares of the medical technology company's stock after selling 222,726 shares during the period. Synergy Asset Management LLC's holdings in Medtronic were worth $3,369,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of MDT. Artisan Partners Limited Partnership increased its holdings in shares of Medtronic by 2.6% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company's stock worth $117,579,000 after purchasing an additional 31,314 shares during the period. SageView Advisory Group LLC lifted its stake in shares of Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company's stock valued at $2,305,000 after buying an additional 15,062 shares during the period. CSM Advisors LLC grew its position in Medtronic by 13.2% during the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company's stock worth $27,169,000 after buying an additional 33,167 shares in the last quarter. UMB Bank n.a. grew its position in Medtronic by 65.8% during the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company's stock worth $13,170,000 after buying an additional 54,898 shares in the last quarter. Finally, Applied Finance Capital Management LLC bought a new position in Medtronic during the third quarter valued at about $1,308,000. Institutional investors own 82.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MDT shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $120.00 price target on shares of Medtronic in a report on Thursday. William Blair upgraded Medtronic from a "market perform" rating to an "outperform" rating in a research report on Tuesday, January 6th. Mizuho upgraded Medtronic to a "strong-buy" rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Medtronic in a research report on Monday, December 29th. Finally, Truist Financial decreased their price target on shares of Medtronic from $107.00 to $103.00 and set a "hold" rating on the stock in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $110.74.

Medtronic Stock Down 0.2%

Shares of MDT opened at $87.72 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $95.99 and a two-hundred day moving average price of $96.52. The stock has a market cap of $112.62 billion, a price-to-earnings ratio of 24.43, a P/E/G ratio of 2.26 and a beta of 0.71. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the company posted $1.38 EPS. The company's revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date is Friday, March 27th. Medtronic's dividend payout ratio is 79.11%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham reaffirmed a Buy on MDT with a $120 price target, highlighting confidence in Medtronic’s multi‑year growth story and tuck‑in acquisition strategy, which supports upside expectations. Needham Reiterates Buy
• Positive Sentiment: FDA expanded the indication for the OmniaSecure defibrillation lead to allow placement in the left bundle branch area, broadening use for conduction‑system pacing and potentially increasing adoption in cardiac device procedures. OmniaSecure FDA Approval
• Positive Sentiment: Medtronic expanded its pain portfolio via a distribution agreement with Merit Medical to offer the FDA‑cleared ViaVerte basivertebral nerve ablation system — a minimally invasive, implant‑free option for chronic low‑back pain that can drive incremental sales in pain management. ViaVerte Distribution Deal
• Positive Sentiment: Market commentary reiterates the planned spin‑off of Medtronic’s high‑growth diabetes unit later this year — a strategic move investors view as value‑unlocking by creating a pure‑play diabetes company and a leaner core medtech business. Spin-Off Thesis
• Neutral Sentiment: Analyst coverage and articles (Zacks, TipRanks, others) largely frame recent news as mixed but keep consensus sentiment constructive — analysts expect multi‑year EPS growth despite the recent charge. Analyst Commentary
• Negative Sentiment: Medtronic cut FY‑2026 guidance after taking a charge tied to MiniMed approval and private equity considerations; this near‑term hit to earnings outlook is the primary reason shares are down as investors reassess short‑term profitability. Guidance Cut / MiniMed Charge

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.26% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.